A Study of LY3872386 in Healthy Participants and Participants With Atopic Dermatitis
Status:
Recruiting
Trial end date:
2026-01-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the safety and tolerability of LY3872386 in
healthy participants and participants with atopic dermatitis. The safety of prednisone is
also evaluated in healthy participants. Blood tests will be performed to investigate how the
body processes the LY3872386 following single and multiple dosing in healthy participants and
participants with atopic dermatitis. Blood tests will also be performed to investigate how
the body processes the prednisone in healthy participants. The study is conducted in three
parts (part A, B and C). The study will last up to approximately 85, 183 and 44 days for
parts A, B, and C, respectively.